

Ticket #:	Request Date:	Request Time:

PHYSICIAN CERTIFICATION PRIOR AUTHORIZATION FORM

A request for the patient identified below has been made for the dispensing of **Iclusig®** ponatinib. Based on recent clinical information, we require more information before this prescription can be paid by the patient's pharmacy benefit plan. Please fill out the following information and return to us as indicated below:

A. Member Information									
Patient Name:		Plan Name/Plan ID:							
Patient ID:		Patient Date of Birth:		Patient Contact Phone #:					
B. Physician Information									
Physician Name:	Physicia	an Address:							
,			l pu di di E	ш					
Physician DEA #:	Physician Phone #:		Physician Fax #:						
Drug Name and Strength:	Direction (SIG):		QTY and Days Supply:			NDC #:			
O. Dhamasan lafa mastica									
C. Pharmacy Information Pharmacy Name: NABP #:		Pharmac	Pharmacy Phone #:		Pharma	ıcy Fax #:			
•						•			
D. Clinical Information (Please fill	out the following informat	tion: circle all that app	y)						
1. Does the patient have chronic myelogenous leukemia (CML) in chronic, accelerated, or blast phase?							YES	NO	
2. Does the patient have Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)?							YES	NO	
3. Has the patient been resistant or intolerant to prior tyrosine kinase inhibitor therapy?						YES	NO		
 If YES to #3, please document which TK inhibitors patient is intolerant to, or has failed in the past. (Note: must be one of either Dasatinib, Bosutinib, Imatinib Mesylate, or Nilotinib HCL.) 									
Authorized Medical Signature:									
Telephone:			Date:				·		

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507 1-866-965-Drug (3784) / Fax # 866-999-7736

**Please note that this form is to be completed by the prescribing physician. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). HIPAA does restrict the communication of PHI with providers for TPO related purposes.